by Eric Christianson | Jan 5, 2025 | Gastrointestinal Medication and Disease State Clinical Pearls
I’ve had some wonderful guest posts in the past and I couldn’t help but notice this awesome post on LinkedIn from a fellow pharmacist! April Oliveros is the author of this quick hitter on “Does Every Patient On Anticoagulation Need a PPI?” You...
by Eric Christianson | Aug 28, 2024 | Cardiovascular Medication and Disease State Clinical Pearls
Rivaroxaban is classified as a direct oral anticoagulant. It is one of the most commonly used anticoagulants within this class (in addition to apixaban). In this blog post, I’ll share the 5 most important rivaroxaban clinical pearls that may appear in practice...
by Eric Christianson | May 22, 2024 | Cardiovascular Medication and Disease State Clinical Pearls
I have many patients who take garlic supplements. One of the interactions I remember learning in pharmacy school is that garlic has the potential to increase the risk of bleeding when taken in combination with blood-thinning medications such as warfarin, DOACs,...
by Eric Christianson | Mar 1, 2023 | Drug Interaction Case Studies and Education For Pharmacists
Apixaban (Eliquis) is an anticoagulant used for stroke prophylaxis in atrial fibrillation, and treatment and prophylaxis of DVT/PE. Its use has grown exponentially since it was first FDA-approved. When it comes to patient medications, apixaban is not exempt from...
by Eric Christianson | Jun 26, 2022 | Drug Interaction Case Studies and Education For Pharmacists
Noval oral anticoagulants (NOACs) are non-vitamin K antagonists that include apixaban (pharmacology podcast), dabigatran, rivaroxaban, and edoxaban. NOACs are highly predictable and are less likely to interact with other medications, making them more favorable than...
